# Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)

> **NCT00326417** · PHASE1,PHASE2 · COMPLETED · sponsor: **Medical College of Wisconsin** · enrollment: 97 (actual)

## Conditions studied

- Anemia, Aplastic

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide 150mg
- **DRUG:** Cyclophosphamide 100mg
- **DRUG:** Cyclophosphamide 50mg

## Key facts

- **NCT ID:** NCT00326417
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2015-09
- **Final completion:** 2016-01
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2021-10-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00326417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00326417, "Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00326417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*